Last reviewed · How we verify
NCT06011486
Expansion of Virus-Specific Lymphocytes for Cell Therapy
Phase 1 trial testing Lymphocyte infusion (ImmuneCellVir-I) in CMV Viremia in 10 participants. Currently enrolling.
10 June 2025
Quick facts
| Lead sponsor | Hospital Israelita Albert Einstein |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 10 June 2024 |
| Primary completion | 10 June 2025 |
| Estimated completion | 10 June 2026 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Lymphocyte infusion (ImmuneCellVir-I)
Conditions studied
- CMV Viremia — all drugs for CMV Viremia →
- CMV — all drugs for CMV →
Sponsor
Hospital Israelita Albert Einstein
Who can join
Adults 18 to 75, any sex, with CMV Viremia or CMV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Infections and reactivation of human cytomegalovirus (CMV), adenovirus, Epstein-barr and polyoma virus infections are frequent causes of morbidity and mortality and are a source of serious complications in patients undergoing allogeneic bone marrow transplantation. In this project we will prepare specific T lymphocytes from blood donor, select cells CMV-specific by interferon gamma capture and treat patients with CMV viral infections. These cells will be used as antiviral therapy in transplanted patients whom do not respond to conventional therapies or in patients whose conventional therapy may be toxic in the context of transplantation. In this context, CMV reactivation can lead to serious complications in patients, such as irreversible neurological changes, pulmonary, gastrointestinal and ophthalmologic complications, among others, in addition to prolonged hospitalizations, leading to significant morbidity and mortality , both in the health sector public as private. This project may represent an important therapeutic modality using cell of the shelf as a source of therapy for different patients and contributing to reduced morbidity / mortality after transplantation, as well as a reduction in the hospitalization period.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancing cell-based therapy in sepsis: An anesthesia outlook.
Ye H, Zou X, Fang X. · · 2024 · cited 2× · PMID 38708689 · DOI 10.1097/cm9.0000000000003097
Verify or expand the search:
- PubMed search for NCT06011486
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CMV Viremia
Currently open trials in the same condition.
- NCT07079735 — Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant · Phase 2, PHASE3 · recruiting
- NCT05432778 — Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients · Phase 2 · recruiting
Other Hospital Israelita Albert Einstein trials
Trials by the same sponsor.
- NCT07447674 — ED Post-Discharge Digital Follow-Up: A Communication Comparison · NA · not yet recruiting
- NCT07398222 — Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study · recruiting
- NCT07233837 — Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units · NA · recruiting
- NCT06726707 — COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis · Phase 2, PHASE3 · withdrawn
- NCT07112846 — Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06011486 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Israelita Albert Einstein
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06011486.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing